Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

Article 
CAS 
PubMed 

Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Article 
CAS 
PubMed 

Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401:1655–68.

Article 
CAS 
PubMed 

Google Scholar 

Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29:2133–41.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019;15:1057–66.

Article 
CAS 
PubMed 

Google Scholar 

Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181–95.

Article 
CAS 
PubMed 

Google Scholar 

Gómez-Ulloa D, Amonkar M, Kothari S, Cheung WY, Chau I, Zalcberg JR, et al. Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. BMC Gastroenterol. 2020;20:133.

Article 
PubMed 
PubMed Central 

Google Scholar 

Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Ann Oncol. 2022;33:244–58.

Article 
CAS 
PubMed 

Google Scholar 

Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O’Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Ann Oncol. 2023;34:987–1002.

Article 
CAS 
PubMed 

Google Scholar 

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–237.

Article 
CAS 
PubMed 

Google Scholar 

Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer ☆. Ann Oncol. 2021;32:1475–95.

Article 
CAS 
PubMed 

Google Scholar 

González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833–48.

Article 
PubMed 

Google Scholar 

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆. Ann Oncol. 2023;34:10–32.

Article 
CAS 
PubMed 

Google Scholar 

Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, et al. Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009;27:5727–33.

Article 
CAS 
PubMed 

Google Scholar 

Simkens LHJ, van Tinteren H, May A, ten Tije AJ, Creemers GJM, Loosveld OJL, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385:1843–52.

Article 
CAS 
PubMed 

Google Scholar 

Roviello G, Rodriquenz MG, Aprile G, D’Angelo A, Roviello F, Nobili S, et al. Maintenance in gastric cancer: New life for an old issue? Crit Rev Oncol Hematol. 2021;160:103307.

Article 
PubMed 

Google Scholar 

Gordon A, Fong CYK, Davidson M, Cromarty S, Kidd S, Piadel K, et al. 1515P Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial. Ann Oncol. 2023;34:S853–4.

Article 

Google Scholar 

Fong C, Patel B, Peckitt C, Bourmpaki E, Satchwell L, Cromarty S, et al. Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study. ESMO Open. 2024;9:103622.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Gordon A, Cunningham D, Rajan Z, Fong C, Peckitt C, Satchwell L, et al. Maintenance capecitabine plus ramucirumab after first-line chemotherapy in patients with advanced esophagogastric adenocarcinoma: results from the randomized PLATFORM study. JCO Oncol Adv. 2025.

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.

Article 
CAS 
PubMed 

Google Scholar 

Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30:19–33.

Article 
CAS 
PubMed 

Google Scholar 

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Ann Oncol. 2022;33:1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.

Article 
CAS 
PubMed 

Google Scholar 

Lisa Hang N, McMillian N, MaryElizabeth Stein M, Ajani JA, D TA, Chair V, et al. NCCN Guidelines Version 4.2024 Gastric Cancer NCCN Evidence Blocks TM Continue NCCN Guidelines Panel Disclosures [Internet]. 2024. Available from: www.nccn.org/patents

Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1–25.

Article 

Google Scholar 

Wang F, Zhang X, Tang L, Wu Q, Cai M, Li Y, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 2024;44:127–72.

Article 
CAS 

Google Scholar 

Lordick F, Al-Batran SE, Arnold D, Borner M, Bruns CJ, Eisterer W, et al. German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer. 2024;27:6–18.

Article 
PubMed 

Google Scholar 

Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W, et al. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018;21:782–91.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Lee GJ, Kim H, Cho SS, Park HS, An HJ, Woo IS, et al. A randomized phase III study of patients with advanced gastric adenocarcinoma without progression after six cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical Observation. J Gastric Cancer. 2023;23:315.

Article 
PubMed 
PubMed Central 

Google Scholar 

Park SR, Kim MJ, Nam BH, Kim CG, Lee JY, Cho SJ, et al. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. Eur J Cancer. 2017;83:32–42.

Article 
CAS 
PubMed 

Google Scholar 

Stocker G, Lorenzen S, Ettrich T, Herz AL, Longo F, Kiani A, et al. S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial. ESMO Open. 2023;8:101572.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Damato A, Bilancia D, Iachetta F, Strippoli A, Filiali F, Casaretti R, et al. 421P Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidines-based chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016). Ann Oncol. 2024;35:S171. https://doi.org/10.1016/j.annonc.2024.05.335.

Article 

Google Scholar 

Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J Clin Oncol. 2021;39:966–77.

Article 
CAS 
PubMed 

Google Scholar 

Ciardiello F, Bang Y, Cervantes A, Dvorkin M, Lopez CD, Metges J, et al. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results. Cancer Med. 2023;12:13145–54.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, et al. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25:1539–50.

Article 
CAS 
PubMed 

Google Scholar 

Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, et al. The Role of Maintenance Strategies in Metastatic Colorectal Cancer. JAMA Oncol. 2020;6:e194489.

Article 
PubMed 
PubMed Central 

Google Scholar